Also categorized in BoardNews:
Six Years Later, The Problem at HP is Still the Board
x hide permanently

Activist investor Bill Ackman to Allergan Execs: I've never seen a board behave as badly as you have".

“What legitimate board of directors attempts to silence or otherwise delay hearing what its own shareholders have to say?” Nearly 90% of Allergan stock has traded at prices above $160 per share since the Valeant bid was made public in April, Mr. Ackman ...

Mentions: Board of Directors